Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
BH4 treatment did increase SAM but the difference was only borderline statistically significant [ F (1, 26) = 3.03, p = 0.09
Cardiovascular risk2.4mg/wk The dose tested in the cardiovascular outcomes trial, which cut major adverse cardiovascular events by 20% in people with established cardiovascular disease and no diabetes
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
In vitro metabolism of 3, 3, 4, 4-tetrachlorobiphenyl in relation to ethoxyresorufin-O-deethylase activity in liver microsomes of some wildlife species and rat
US$ 21.60
US$ 29.29
US$ 21.42
US$ 21.02
US$ 26.13
US$ 22.98
US$ 27.61
